Lantheus Holdings, Inc. Stock

Equities

LNTH

US5165441032

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
65.21 USD +1.24% Intraday chart for Lantheus Holdings, Inc. +6.07% +5.18%
Sales 2024 * 1.43B Sales 2025 * 1.52B Capitalization 4.42B
Net income 2024 * 331M Net income 2025 * 434M EV / Sales 2024 * 3.08 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.9 x
P/E ratio 2024 *
14.1 x
P/E ratio 2025 *
11 x
Employees 834
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.57%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.24%
1 week+5.64%
Current month+4.77%
1 month+10.49%
3 months+24.26%
6 months-3.79%
Current year+5.18%
More quotes
1 week
61.47
Extreme 61.47
65.54
1 month
57.92
Extreme 57.92
65.54
Current year
50.20
Extreme 50.2
69.73
1 year
50.20
Extreme 50.2
100.85
3 years
19.30
Extreme 19.301
100.85
5 years
8.67
Extreme 8.67
100.85
10 years
1.76
Extreme 1.76
100.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 12-08-31
President 43 20-01-26
Director of Finance/CFO 57 18-09-20
Members of the board TitleAgeSince
Chief Executive Officer 64 12-08-31
Director/Board Member 80 18-01-31
Director/Board Member 78 12-04-30
More insiders
Date Price Change Volume
24-04-24 65.21 +1.24% 581,963
24-04-23 64.41 +2.12% 591,933
24-04-22 63.07 -1.16% 652,015
24-04-19 63.81 +2.37% 798,463
24-04-18 62.33 +1.38% 1,271,332

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
65.21 USD
Average target price
94.11 USD
Spread / Average Target
+44.32%
Consensus